StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for ALT yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $2.90 | $2.85 | -1.72% | 2.3M |
| 05-18 | $2.85 | $2.80 | -1.75% | 3.5M |
| 05-19 | $2.80 | $2.74 | -2.14% | 2.5M |
| 05-20 | $2.75 | $2.82 | +2.55% | 2.2M |
| 05-21 | $2.80 | $2.93 | +4.64% | 3.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q3 2022 2022-09-30 | Q2 2022 2022-06-30 | Q1 2022 2022-03-31 | Annual 2021 2021-12-31 |
|---|---|---|---|---|
Revenue | $42.00K | $40.00K | $32.00K | $4.41M |
Operating Income | $-64.65M | $-39.89M | $-19.50M | $-96.91M |
Net Income | $-63.05M | $-20.11M | $-19.43M | $-97.09M |
EPS (Diluted) | $-1.37 | $-0.90 | $-0.44 | $-2.35 |
Total Assets | $225.28M | $209.91M | $205.66M | $218.87M |
Total Liabilities | $20.25M | $15.37M | $20.79M | $19.73M |
Cash & Equivalents | $127.47M | $135.86M | $179.95M | $190.30M |
Free Cash Flow OCF − CapEx | $-45.37M | $-30.26M | $-13.54M | $-90.36M |
Shares Outstanding | 49.16M | 46.37M | 43.22M | 40.99M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.